MedTrace Logo

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

NCT00057239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 546

Last updated 2010-10-04

No results posted yet for this study

Summary

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Radafaxine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, M.D. · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2004-05-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00057239 on ClinicalTrials.gov